Table 4.

Comparison of CAR T, NK, and macrophages in solid tumors treatment

Criteria	CAR-T	CAR-NK	CAR-M
Cell sources	-­ PB (autologous/ allogeneic) -­ Rarely from iPSC and UCB	-­ UCB ­- BM -­ hESCs -­ IPSCs -­ NK92 cell line ­- PB	­- UCB ­- BM ­- hESCs ­- IPSCs ­- HPSCs ­- THP1 cell line ­- PB
Availability	-­ Autologous -­ MHC-matched allogeneic CAR-T cells -­ Unlikely “Off-the-shelf” product	-­ Autologous -­ Off-the-shelf CAR-NK product	-­ Autologous -­ Off-the-shelf CAR-M product
In vivo safety and persistence	-­ Long-term persistence, -­ On-target/off-tumor toxicity -­ GVHD, CRS and Neurotoxicity	-­ Limited lifespan -­ Reduced on-target/off-tumor toxicity -­ GVHD, no CRS nor Neurotoxicity.	-­ Limited time in circulation -­ Less On-target/off-tumor toxicity -­ No GVHD -­ CRS and Neurotoxicity
FDA-regulated CAR-cell products	-­ P-MUC1C-ALLO1 CAR-T cells (NCT05239143) -­ GD2 CAR T cells (NCT04196413) -­ GD2 CAR T cells (NCT00085930) -­ ROR1 CAR-T cells (LYL797) (NCT05274451) -­ ROR1 CAR-T cells (NCT02706392) -­ HER2 CAR-T cells (NCT03740256) -­ B7-H3 CAR-T cells (NCT04897321) -­ B7-H3 CAR-T cells (NCT04483778) -­ PSCA CAR-T cells (BPX-601) (NCT02744287) -­ PSCA CAR-T cells (NCT02744287)	-­ MICA/B CAR-NK cells (FT536) (NCT05395052)	-­ HER2 CAR-Macrophage (CT-0508) (NCT04660929)